Amelioration of Hypoglycemia Via Somatostatin Receptor Type 2 Antagonism in Recurrently Hypoglycemic Diabetic Rats

• Published in: Diabetes (New York, N.Y.) Vol. 62; no. 7; pp. 2215 - 2222
• Main Authors: YUE, Jessica T. Y, RIDDELL, Michael C, BURDETT, Elena, COY, David H, EFENDIC, Suad, VRANIC, Mladen
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.07.2013
• Subjects: Animals; Biological and medical sciences; Blood Glucose; Body Weight - drug effects; Catecholamines - blood; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - metabolism; Diabetes. Impaired glucose tolerance; Eating - drug effects; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Endokrinologi och diabetes; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Glucagon - blood; Hypoglycemia - chemically induced; Hypoglycemia - drug therapy; Hypoglycemia - metabolism; Insulin - blood; Klinisk medicin; Medical sciences; Medicin och hälsovetenskap; Original Research; Peptides, Cyclic - pharmacology; Peptides, Cyclic - therapeutic use; Rats; Receptors, Somatostatin - antagonists & inhibitors; Endocrinopathy; Rat; Diabetes mellitus; Peptide hormone; Rodentia; Metabolic diseases; Hypoglycemia; Neuropeptide; Vertebrata; Mammalia; Animal; Somatostatin; Biological receptor
• ISSN: 0012-1797; 1939-327X; 1939-327X
• DOI: 10.2337/db12-1523

Selective antagonism of somatostatin receptor type 2 (SSTR2) normalizes glucagon and corticosterone responses to hypoglycemic clamp in diabetic rats. The purpose of this study was to determine whether SSTR2 antagonism (SSTR2a) ameliorates hypoglycemia in response to overinsulinization in diabetic rats previously exposed to recurrent hypoglycemia. Streptozotocin diabetic rats (n = 19), previously subjected to five hypoglycemia events over 3 days, received an insulin bolus (10 units/kg i.v.) plus insulin infusion (50 mU/kg/min i.v.) until hypoglycemia ensued (≤3.9 mmol/L) (experimental day 1 [Expt-D1]). The next day (Expt-D2), rats were allocated to receive either placebo treatment (n = 7) or SSTR2a infusion (3,000 nmol/kg/min i.v., n = 12) 60 min prior to the same insulin regimen. On Expt-D1, all rats developed hypoglycemia by ∼90 min, while on Expt-D2, hypoglycemia was attenuated with SSTR2a treatment (nadir = 3.7 ± 0.3 vs. 2.7 ± 0.3 mmol/L in SSTR2a and controls, P < 0.01). Glucagon response to hypoglycemia on Expt-D2 deteriorated by 20-fold in the placebo group (P < 0.001) but improved in the SSTR2a group (threefold increase in area under the curve [AUC], P < 0.001). Corticosterone response deteriorated in the placebo-treated rats on Expt-D2 but increased twofold in the SSTR2a group. Catecholamine responses were not affected by SSTR2a. Thus, SSTR2 antagonism after recurrent hypoglycemia improves the glucagon and corticosterone responses and largely ameliorates insulin-induced hypoglycemia in diabetic rats.